EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G/A filing with the Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated April 30, 2024, was submitted by Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, who collectively reported shared voting and dispositive power over 5,156,299 shares of EyePoint Pharmaceuticals' common stock. This stake represents 9.90% of the company's class of securities. The filing amends and replaces the previous Schedule 13G filed on the same date in 2023. The shares are reported to be held in the ordinary course of business, with no intention of changing or influencing the control of the issuer. The principal business office for the reporting persons is located at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts.

EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G/A filing with the Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated April 30, 2024, was submitted by Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, who collectively reported shared voting and dispositive power over 5,156,299 shares of EyePoint Pharmaceuticals' common stock. This stake represents 9.90% of the company's class of securities. The filing amends and replaces the previous Schedule 13G filed on the same date in 2023. The shares are reported to be held in the ordinary course of business, with no intention of changing or influencing the control of the issuer. The principal business office for the reporting persons is located at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts.